Original article:

**N1-BENZENESULFONYL-2-PYRAZOLINE HYBRIDS IN NEUROLOGICAL DISORDERS: SYNTHESES, BIOLOGICAL SCREENING AND COMPUTATIONAL STUDIES**

Avinash C. Tripathi¹, Savita Upadhyay¹, Sarvesh Paliwal², Shailendra K. Saraf*¹

1 Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, Lucknow-226028, U.P., India
2 Professor and Head, Department of Pharmacy, Banasthali Vidyapith, Banasthali, Tonk-304022, Rajasthan, India

E-mails: aviniec31@gmail.com; savvypharma@gmail.com; y paliwalsarvesh@yahoo.com; dirpharmniec@gmail.com

* Corresponding author: Prof. (Dr.) Shailendra K. Saraf, Director (Pharmacy), Division of Pharmaceutical Chemistry, Faculty of Pharmacy, Babu Banarasi Das Northern India Institute of Technology, BBD City, Faizabad Road, Chinhat, Lucknow-226028, U.P., India.

Voice Contact: +91-522-3911052 (office), +919839228022 (mobile),
Fax: +91-522-3911152, E-mail: dirpharmniec@gmail.com

http://dx.doi.org/10.17179/excli2017-871

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/).

**ABSTRACT**

A novel series of 1,3,5-trisubstituted-2-pyrazolines (5a-5t) was prepared via Claisen Schmidt condensation, followed by heterocyclization with hydrazine hydrate, substitution of N1 hydrogen of 2-pyrazoline nucleus with 4-chlorobenzencesulfonfylchloride, applying conventional and green chemistry approaches. Among the two, microwave-assisted organic synthesis (MAOS) emerged as a better synthetic tool in terms of faster reaction rate and high yield. Various physicochemical and spectral studies were conducted to characterize the synthesized derivatives including IR, Mass, 1H-NMR, 13C-NMR and elemental analysis. During pharmacological evaluation, compound 5b showed excellent anti-anxiety activity and compound 5k exhibited the best antidepressant effect at the tested doses, 50 and 100 mg/kg b.w., being comparable to diazepam and imipramine, respectively. The docking experiments confirmed the probable mechanism of neuropharmacological action, showing excellent affinity towards MAO-A target protein, which was also evidenced from some of the key interactions with binding site residues Ala68, Tyr69 and Phe352. Furthermore, complimentary *in silico* pharmacokinetic recital without any potential risk of neurotoxicity (as evaluated by rotarod and actophotometer tests), or carcinogenicity, mutagenicity, reproductive toxicity, acute toxicity and irritancy (as predicted by LAZAR and OSIRIS programs) signified their probable use in depression and anxiety disorders.

**Keywords:** 2-Pyrazolines, antidepressant and anti-anxiety, neurotoxicity, microwave synthesis, molecular docking, *in silico* ADME prediction

**INTRODUCTION**

Monoamine oxidase (MAO) regulates monoaminergic homeostasis and neurotransmission in the nervous system. Low level of certain neurotransmitters (NTs) in the brain, like dopamine (DA), norepinephrine (NE), serotonin (5-HT), and gamma amino butyric acid (GABA), is the main cause of depressive mental disorders. These NTs are released during neurotransmission and are degraded by the MAOs enzymes.
Monoamine oxidase inhibitors (MAOIs) block the action of MAOs, and thus increase the concentration of NTs in the brain (Mitoma and Ito, 1992; Meyer et al., 2006). The antidepressant effect of a hydrazine based anti-tubercular drug, iproniazid (a structural analog of isoniazid) started the journey of development of MAOIs. This discovery showed the way to design and produce some more effective analogs such as phenelzine (Zeller and Barsky, 1952). MAOIs belong to the first generation antidepressants used for decades to treat the patients suffering from high level of anxiety, atypical depression (Pletscher, 1991), anergic bipolar depression and treatment resistant depression (Thase, 2012), specific phobias, post-traumatic stress disorder and migraine headaches resistant to other therapies (Gareri et al., 2000). Two major therapeutic categories of MAOIs: the MAO-A inhibitors in certain mental disorders such as depression and anxiety (Amrein et al., 1999) and MAO-B inhibitors proved their remedial value in neurodegenerative diseases (Youdim et al., 2006; Foley et al., 2000) including Parkinson’s (Cesura and Pletscher, 1992) and Alzheimer’s (Volz and Gleiter, 1998). The initial hydrazine class of MAO inhibitors was associated with some severe adverse effects such as liver toxicity and cheese reaction (Brown et al., 1989). These side-effects were correlated to nonselective and irreversible MAO inhibition. These findings prompted research to develop selective and reversible type of MAO (A and B) inhibitors. Pyrazoline derivatives have attracted substantial attention for years, chiefly 1,3,5-trisubstituted-2-pyrazoline pharmacophore is allied with encouraging neurological activities such as tranquilizer, anticonvulsant and antidepressant (Kaplancikli et al., 2010; Ozdemir et al., 2008; Palaska et al., 2001; Rajendra Prasad et al., 2005; Ruhoglu et al., 2005), psychoanaleptic, MAO inhibitory and other biological activities (Chimenti et al., 2004; 2010; Gokhan et al., 2003; Gokhan-Kelekci et al., 2009; Jagrat et al., 2011; Jayaprakash et al., 2008; Karuppasamy et al., 2010; Maccioni et al., 2010; Manna et al., 2002; Mishra and Sasmal, 2011; Sahoo et al., 2010; Agrawal et al., 2012; Gautam et al., 2010). Considering these facts, some 1,3,5-trisubstituted-2-pyrazolines were synthesized by integrating some novel aromatic and hetero-aromatic substitutions at 3rd and 5th positions, respectively. Microwave facilitated synthetic technique was also utilized to prepare the proposed compounds and the results were compared to that of the conventional heating methods (Lidstrom et al., 2001). This work is in continuation to the previous communications by our group (Tripathi et al., 2016, Upadhyay et al., 2017; Bhandari et al., 2013) with some novel derivatives having promising potential in the field.

MATERIALS AND METHODS

S. D. Fine Chemicals and Sigma Aldrich, Mumbai, India supplied the chemicals and reagents for synthesis and the pre-coated TLC sheets were obtained from Merck Chemicals, India and were used as such. Microwave assisted organic synthesis (MAOS) was performed on Raga’s Scientific Microwave System (Ragatech, Pune, Maharashtra, India).

Chemistry

The reaction of suitably substituted aromatic/heteroaromatic ketones with different aldehydes, in alkaline medium, yielded substituted chalcones (1a-1t) via Claisen-Schmidt condensation. Then, the formed chalcones were reacted with hydrazine hydrate (in excess) to give 2-pyrazoline derivatives (2a-2t). Finally, the N1 hydrogen of the 2-pyrazoline nucleus was replaced with 4-chlorobenzenesulfonylchloride (5a-5t), as given in Figure 1. The reaction progress was examined by thin layer chromatography (TLC), using pre-coated silica gel G plates as stationary phase and iodine vapors/UV light as the visualizing agents.
**Synthesis of chalcone derivatives (1a-1t)**

The proposed chalcone derivatives of the first step were synthesized by reacting suitably substituted aldehydes and ketones, in equimolar ratio, via conventional and microwave assisted organic synthesis (MAOS) procedures (Tripathi et al., 2016; Upadhyay et al., 2017; Agrawal et al., 2012; Gautam et al., 2010).

**Synthesis of 3,5-disubstituted-2-pyrazoline derivatives (2a-2t)**

The 3,5-disubstituted-2-pyrazoline derivatives of the second step were synthesized by reacting different chalcone derivatives of the first step with hydrazine hydrate (excess), using conventional and MAOS procedures (Tripathi et al., 2016; Upadhyay et al., 2017).
Synthesis of 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t)

Conventional synthesis: Appropriately substituted 2-pyrazoline derivatives (0.001M) of the second step reacted with 4-chlorobenzenesulfonyl chloride (0.002M) by stirring, using THF (10 mL) as the solvent. Continued the stirring for 1-4 hrs, poured the reaction mixture in a petri plate and evaporated the solvent up to dryness. Recrystallized the crude product using acetonitrile/methanol and re-crystallized from acetonitrile/methanol to obtain the pure product (Upadhyay et al., 2017).

MAOS: Appropriately substituted 3,5-disubstituted-2-pyrazolines (0.001M) were reacted with 4-chloro benzenesulfonyl chloride (0.002M) under microwave irradiation (MWI: 210-350W; 80-280s), taking THF (10 mL) as the solvent. The reaction mixture was poured in a petri plate and evaporated the solvent up to dryness. The crude product was re-precipitated using acetonitrile/methanol and recrystallized from acetonitrile/methanol to get the purified derivative (Upadhyay et al., 2017).

Characterization of the synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives

First and second step intermediate compounds were characterized by TLC, melting point (determined by open capillary method and are uncorrected) and mass spectrometric techniques. However, comprehensive physicochemical (Table 1) and spectral characterization was undertaken for the final derivatives and the values were found to be in agreement.

4-[1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5a)

IR spectra were recorded onBruker FT-IR, ALPHA-T (Eco-ATR) spectrophotometers, (Bruker Corporation., USA) and the values are expressed in cm\(^{-1}\). 3220 (N-H stretch), 2865 (C-H Aromatic), 1650 (C=N stretch), 1515 (C-H deform), 1159, 1350 (sym., asym S(=O)\(_2\) stretch). \(^1\)H-NMR and \(^{13}\)C-NMR spectra were recorded on Bruker Avance-400, FTNMR spectrometer (Bruker, Tech. Pvt. Ltd., USA) at 400MHz and the chemical shifts are reported in parts per million (\(\delta\) value), taking TMS (\(\delta\) 0 ppm for \(^1\)H NMR) as the internal standard: 2.03-2.09 (dd, \(J\text{ab}: \) 16.77 Hz, \(J\text{ax}: 3.58 \text{ Hz, 1H, } H_a\)), 2.73-2.78 (dd, \(J\text{ab}: 3.85 \text{ Hz, } J\text{ax}: 17.11 \text{ Hz, 1H, } H_b\)), 3.81-3.93 (dd, \(J\text{ax}: 3.50 \text{ Hz, } J\text{bx}: 17.05 \text{ Hz, 1H, } H_x\)), 5.23-5.25 (s, 1H, Ar-OH), 6.56-7.90 (m, 11H, Ar). \(^{13}\)C NMR (DMSO, ppm): 37.9 (CH\(_3\) pyrazoline), 43.0 (CH pyrazoline), 113.8-146.3 (12CH benzene), 147.5-159.2 (7C benzene), 160.1 (C pyrazoline). Mass spectra were recorded on Waters UPLC-TQD Mass Spectrometer instrument (Waters Corporation, USA) using LC-ESI or APCI-MS Technique; MS (m/z): 473 (M\(^+\), 100 %).

Elemental analysis was performed on Perkin Elmer-2400, Series-II Analyzer (Waltham, Massachusetts, USA). Anal. Calcd. for C\(_{23}\)H\(_{21}\)ClN\(_2\)O\(_5\)S: C, 58.41; H, 4.48; N, 5.92. Found: C, 58.39; H, 4.50; N, 5.89.

4-[1-(4-Chloro-benzenesulfonyl)-5-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5b)

IR (cm\(^{-1}\)): 3359 (N-H stretch), 3142 (C-H Aromatic), 1606 (C=N stretch), 1516 (C-H deform), 1165, 1351 (sym., asym S(=O)\(_2\) stretch). \(^1\)H-NMR (\(\delta\) ppm, DMSO): 1.98-1.99 (dd, \(J\text{ab}: 17.12 \text{ Hz, } J\text{ax}: 3.41 \text{ Hz, 1H, } H_a\)), 3.40-3.48 (dd, \(J\text{ab}: 4.01 \text{ Hz, } J\text{ax}: 16.23 \text{ Hz, 1H, } H_b\)), 3.70-3.80 (dd, \(J\text{ax}: 3.28 \text{ Hz, } J\text{bx}: 17.46 \text{ Hz, 1H, } H_x\)), 5.39-5.45 (s, 1H, Ar-OH), 6.88-7.89 (m, 12H, Ar). \(^{13}\)C NMR (DMSO, ppm): 38.6 (CH\(_2\) pyrazoline), 43.2 (CH pyrazoline), 115.6-140.3 (12CH benzene), 158.3-160.1 (3C benzene), 161.2 (C pyrazoline). MS (m/z): 447 (M\(^+\), 100 %).

Anal. Calcd. for C\(_{21}\)H\(_{16}\)Cl\(_2\)N\(_2\)O\(_3\)S: C, 56.38; H, 3.61; N, 6.26. Found: C, 57.42; H, 3.59; N, 6.24.
Table 1: Comparative study of physicochemical properties of synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t)

| Compounds | Structure | Molecular Formula | Color and State | Solubility | Rf Value | Melting Range (°C) | Conventional Synthesis (Refluxing) | Microwave Assisted Organic Synthesis (MAOS) |
|-----------|-----------|-------------------|-----------------|------------|----------|-------------------|-----------------------------------|-----------------------------------------------|
|           |           |                   |                 |            |          |                   | Reaction Time (h) | % Yield | Microwave Power (W) | Reaction Time (s) | % Yield |
| 5a        | ![Structure](image1.png) | C_{22}H_{21}ClIN_{2}O_{5}S | Cream yellow colored amorphous solid | Acetonitrile, acetone, DMSO | 0.67 | 206-208 | 2.5 | 47 | 210-240 | 130 | 66 |
| 5b        | ![Structure](image2.png) | C_{21}H_{16}Cl_{2}N_{2}O_{3}S | Colorless crystalline solid | Methanol, DMSO, chloroform, acetone | 0.92 | 198-200 | 2.0 | 68 | 210 | 85 | 70 |
| 5c        | ![Structure](image3.png) | C_{19}H_{15}ClIN_{2}O_{4}S | Light brown colored amorphous solid | Methanol, acetonitrile, chloroform, acetone, DMSO | 0.88 | 162-164 | 4.5 | 58 | 240-280 | 210 | 81 |
| 5d        | ![Structure](image4.png) | C_{19}H_{15}ClIN_{2}O_{3}S_{2} | Brown colored amorphous solid | Methanol, acetonitrile, acetone, DMSO | 0.75 | 148-150 | 3.5 | 57 | 240-350 | 200 | 82 |
| 5f        | ![Structure](image5.png) | C_{21}H_{15}Cl_{3}N_{2}O_{3}S | Grey colored amorphous solid | Methanol, acetonitrile, chloroform, acetone, DMSO | 0.52 | 185-187 | 2.0 | 45 | 210-240 | 150 | 78 |
| Compounds | Structure | Molecular Formula | Color and State | Solubility | R<sub>f</sub> Value | Melting Range (°C) | Conventional Synthesis (Refluxing) | Microwave Assisted Organic Synthesis (MAOS) |
|-----------|-----------|------------------|----------------|------------|--------------------|-------------------|------------------------------|-----------------------------------------|
|           |           |                  |                |            | Reaction Time (h)  | % Yield            | Microwave Power (W) | Reaction Time (s) | % Yield  |
| 5g        | ![Structure](image1) | C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>3</sub>S | Black colored amorphous solid | Acetonitrile, acetone, DMSO | 0.80 | 120-122 | 4.0 | 45 | 240-350 | 130 | 86 |
| 5h        | ![Structure](image2) | C<sub>19</sub>H<sub>14</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S<sub>2</sub> | Yellowish brown colored amorphous solid | Acetonitrile, acetone, DMSO | 0.66 | 193-195 | 2.5 | 57 | 280-350 | 100 | 70 |
| 5i        | ![Structure](image3) | C<sub>27</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>4</sub>S | Orange brown colored amorphous solid | Methanol, acetone, DMSO | 0.92 | 168-170 | 1.0 | 48 | 210-280 | 100 | 63 |
| 5j        | ![Structure](image4) | C<sub>25</sub>H<sub>18</sub>Cl<sub>2</sub>N<sub>2</sub>O<sub>2</sub>S | Cream colored amorphous solid | Acetonitrile, acetone, DMSO | 0.58 | 178-180 | 2.5 | 51 | 280 | 80 | 85 |
| 5k        | ![Structure](image5) | C<sub>23</sub>H<sub>17</sub>ClN<sub>2</sub>O<sub>3</sub>S | Black colored amorphous solid | Acetone, DMSO, acetonitrile | 0.77 | 218-220 | 3.0 | 32 | 210-280 | 220 | 86 |
| Compounds | Structure | Molecular Formula | Color and State | Solubility | Rf Value | Melting Range (°C) | Conventional Synthesis (Refluxing) | Microwave Assisted Organic Synthesis (MAOS) |
|-----------|-----------|-------------------|----------------|------------|----------|-------------------|-----------------------------------|--------------------------------------|
| 5l        | ![Structure](5l.png) | C_{23}H_{17}ClN_{2}O_{2}S_{2} | Black colored amorphous solid | Acetonitrile, acetone, DMSO | 0.64 | 112-114 | 3.0 97 | 280-350 | 180 94 |
| 5q        | ![Structure](5q.png) | C_{22}H_{20}ClN_{3}O_{4}S | Brown colored amorphous solid | Methanol, acetonitrile, chloroform, acetone, DMSO | 0.90 | 180-182 | 2.5 30 | 280 | 160 71 |
| 5r        | ![Structure](5r.png) | C_{20}H_{15}Cl_{2}N_{3}O_{3}S | Yellowish brown colored amorphous solid | Methanol, acetonitrile, chloroform, acetone, DMSO | 0.78 | 116-118 | 2.0 93 | 210-350 | 175 68 |
| 5t        | ![Structure](5t.png) | C_{18}H_{14}ClN_{3}O_{2}S_{2} | Brown colored amorphous solid | Methanol, acetonitrile, acetone, DMSO | 0.60 | 138-140 | 3.0 48 | 280-350 | 260 72 |
4-[1-(4-Chloro-benzenesulfonyl)-5-furan-2-yl-4,5-dihydro-1H-pyrazol-3-yl]-phenol (5c)

IR (cm\(^{-1}\)): 3472 (N-H stretch), 3239 (C-H Aromatic), 1602 (C=N stretch), 1434 (C-H deform), 1159, 1348 (sym., asym S(=O)\(_2\) stretch).

\(^1\)H NMR (δ ppm, DMSO): 2.14-2.16 (dd, \(J_{ab}: 17.00\) Hz, \(J_{ax}: 3.18\) Hz, 1H, H\(_a\)), 3.27-3.36 (dd, \(J_{ab}: 3.88\) Hz, \(J_{bx}: 16.69\) Hz, 1H, H\(_b\)), 5.20 (s, 1H, Ar-OH), 6.04-7.66 (m, 11H, Ar).

\(^13\)C NMR (DMSO, ppm): 40.1 (CH\(_2\) pyrazoline), 44.5 (CH pyrazoline), 104.2-142.9 (11CH Ar), 135.3-158.6 (4C benzene), 159.0 (C furen), 160.7 (C pyrazoline). MS (m/z): 229 (M\(^+\), 100 %).

Anal. Calcd. for C\(_{19}\)H\(_{15}\)ClN\(_2\)O\(_4\)S: C, 56.65; H, 3.75; N, 6.95. Found: C, 56.66; H, 3.77; N, 6.93.

1-(4-Chloro-benzenesulfonyl)-3,5-bis-(4-chloro-phenyl)-4,5-dihydro-1H-pyrazole (5f)

IR (cm\(^{-1}\)): 3315 (N-H stretch), 3100 (C-H Aromatic), 1616 (C=N stretch), 1465 (C-H deform), 1189, 1382 (sym., asym S(=O)\(_2\) stretch).

\(^1\)H NMR (δ ppm, DMSO): 1.91-1.96 (dd, \(J_{ab}: 17.56\) Hz, \(J_{ax}: 3.50\) Hz, 1H, H\(_a\)), 3.29-3.48 (dd, \(J_{ab}: 4.01\) Hz, \(J_{ax}: 17.23\) Hz, 1H, H\(_b\)), 7.00-7.77 (m, 12H, Ar).

\(^13\)C NMR (DMSO, ppm): 39.0 (CH\(_2\) pyrazoline), 42.5 (CH pyrazoline), 125.8-131.2 (12CH benzene), 136.1-141.9 (4C benzene), 161.2 (C pyrazoline). MS (m/z): 463 (M\(^+\), 55 %). Anal. Calcd. for C\(_{21}\)H\(_{15}\)Cl\(_3\)N\(_2\)O\(_2\): C, 54.15; H, 3.25; N, 6.01. Found: C, 54.11; H, 3.22; N, 6.00.

1-(4-Chloro-benzenesulfonyl)-3-(4-chloro-phenyl)-5-furan-2-yl-4,5-dihydro-1H-pyrazole (5g)

IR (cm\(^{-1}\)): 3270 (N-H stretch), 3010 (C-H Aromatic), 1615 (C=N stretch), 1463 (C-H deform), 1189, 1382 (sym., asym S(=O)\(_2\) stretch).

\(^1\)H NMR (δ ppm, DMSO): 1.99-2.00 (dd, \(J_{ab}: 15.72\) Hz, \(J_{ax}: 3.86\) Hz, 1H, H\(_a\)), 3.40-3.48 (dd, \(J_{ab}: 3.94\) Hz, \(J_{bx}: 16.70\) Hz, 1H, H\(_b\)).

MS (m/z): 419 (M\(^+\), 95 %). Anal. Calcd. for C\(_{19}\)H\(_{15}\)Cl\(_2\)N\(_2\)O\(_3\): C, 54.47; H, 3.61; N, 6.69. Found: C, 54.43; H, 3.67; N, 6.63.

1-(4-Chloro-benzenesulfonyl)-3-(4-chloro-phenyl)-5-thiophen-2-yl-4,5-dihydro-1H-pyrazole (5h)

IR (cm\(^{-1}\)): 3345 (N-H stretch), 3056 (C-H Aromatic), 1618 (C=N stretch), 1539 (C-H deform), 1168, 1355 (sym., asym S(O)\(_2\) stretch).

\(^1\)H NMR (δ ppm, DMSO): 2.08-2.13 (dd, \(J_{ab}: 15.31\) Hz, \(J_{ax}: 2.98\) Hz, 1H, H\(_a\)), 3.61-3.79 (dd, \(J_{ab}: 3.58\) Hz, \(J_{ax}: 16.57\) Hz, 1H, H\(_b\)), 6.53-7.60 (m, 11H, Ar).

\(^13\)C NMR (DMSO, ppm): 39.9 (CH\(_2\) pyrazoline), 42.5 (CH pyrazoline), 105.7-128.5 (11CH Ar), 130.2-136.8 (3C benzene), 159.0 (C furan), 161.7 (C pyrazoline). MS (m/z): 421 (M\(^+\), 65 %). Anal. Calcd. for C\(_{19}\)H\(_{15}\)Cl\(_2\)N\(_2\)O\(_2\): C, 54.17; H, 3.35; N, 6.65. Found: C, 54.20; H, 3.39; N, 6.61.

1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5i)

IR (cm\(^{-1}\)): 3345 (N-H stretch), 3056 (C-H Aromatic), 1612 (C=N stretch), 1471 (C-H deform), 1165, 1393 (sym., asym S(O)\(_2\) stretch).

\(^1\)H NMR (δ ppm, DMSO): 1.97-1.98 (dd, \(J_{ab}: 17.22\) Hz, \(J_{ax}: 3.52\) Hz, 1H, H\(_a\)),

MS (m/z): 437 (M\(^+\), 40 %). Anal. Calcd. for C\(_{19}\)H\(_{14}\)Cl\(_2\)N\(_2\)O\(_2\): C, 52.18; H, 3.23; N, 6.41. Found: C, 52.17; H, 3.20; N, 6.47.

1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5j)

IR (cm\(^{-1}\)): 3315 (N-H stretch), 3100 (C-H Aromatic), 1616 (C=N stretch), 1465 (C-H deform), 1189, 1382 (sym., asym S(O)\(_2\) stretch).

\(^1\)H NMR (δ ppm, DMSO): 1.97-1.98 (dd, \(J_{ab}: 17.22\) Hz, \(J_{ax}: 3.52\) Hz, 1H, H\(_a\)),
3.39-3.47 (dd, $J_{ab}$: 3.87 Hz, $J_{ab}$: 16.73 Hz, 1H, Hs), 3.54-3.69 (dd, $J_{ax}$: 16.73 Hz, 1H, Hs), 3.80-3.94 (m, 6H, methyl), 6.78-7.64 (m, 14H, Ar). $^{13}$C NMR (DMSO, ppm): 39.7 (CH2 pyrazoline), 42.5 (CH pyrazoline), 61.7 (2CH3), 113.7-132.5 (14CH Ar), 130.8-137.2 (7C Ar), 159.3 (C pyrazoline). MS (m/z): 507 (M+, 50 %). Anal. Calcd. for C27H23ClN2O4S: C, 63.96; H, 4.57; N, 5.53. Found: C, 64.07; H, 4.61; N, 5.46.

1-(4-Chloro-benzenesulfonyl)-5-(4-chloro-phenyl)-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5j)

IR (cm$^{-1}$): 3266 (N-H stretch), 3011 (C-H Aromatic), 1570 (C=N stretch), 1495 (C-H deform), 1166, 1362 (sym., asym S(=O)$_2$ stretch). $^1$H NMR ($\delta$ ppm, DMSO): 2.15-2.19 (dd, $J_{ab}$: 16.68 Hz, $J_{ax}$: 3.27 Hz, 1H, Ha), 3.83-3.88 (dd, $J_{ab}$: 3.95 Hz, $J_{bx}$: 17.10 Hz, 1H, Hb), 3.50-3.67 (dd, $J_{ax}$: 4.12 Hz, $J_{bx}$: 16.97 Hz, 1H, Hx), 6.90-7.73 (m, 14H, Ar). $^{13}$C NMR (DMSO, ppm): 39.2 (CH2 pyrazoline), 46.4 (CH pyrazoline), 124.2-129.0 (14CH Ar), 128.5-136.1 (7C benzene), 158.7 (C pyrazoline). MS (m/z): 481 (M+, 50 %). Anal. Calcd. for C25H18Cl2N2O2S: C, 62.37; H, 3.77; N, 5.82. Found: C, 62.49; H, 3.80; N, 5.78.

1-(4-Chloro-benzenesulfonyl)-3-naphthalen-1-yl-5-thiophen-2-yl-4,5-dihydro-1H-pyrazole (5l)

IR (cm$^{-1}$): 3292 (N-H stretch), 3047 (C-H Aromatic), 1570 (C=N stretch), 1495 (C-H deform), 1166, 1362 (sym., asym S(=O)$_2$ stretch). $^1$H NMR ($\delta$ ppm, DMSO): 2.08-2.09 (dd, $J_{ab}$: 17.48 Hz, $J_{ax}$: 2.99 Hz, 1H, Hs). 3.10-3.18 (dd, $J_{ab}$: 3.74 Hz, $J_{bx}$: 17.04 Hz, 1H, Hs), 3.83-3.86 (dd, $J_{ax}$: 3.26 Hz, $J_{bx}$: 16.36 Hz, 1H, Hs), 6.60-7.92 (m, 14H, Ar). $^{13}$C NMR (DMSO, ppm): 40.6 (CH2 pyrazoline), 46.1 (CH pyrazoline), 118.5-129.2 (14CH Ar), 137.8-148.1 (6C Ar), 161.5 (C pyrazoline). MS (m/z): 437 (M+, 50 %), 438 (30 %). Anal. Calcd. for C23H17ClN2O3S: C, 63.23; H, 3.92; N, 6.41. Found: C, 63.26; H, 3.97; N, 6.21.

1-(4-Chloro-benzenesulfonyl)-3-furan-2-yl-3-naphthalen-1-yl-4,5-dihydro-1H-pyrazole (5k)

IR (cm$^{-1}$): 3290 (N-H stretch), 3011 (C-H Aromatic), 1570 (C=N stretch), 1495 (C-H deform), 1166, 1362 (sym., asym S(=O)$_2$ stretch). $^1$H NMR ($\delta$ ppm, DMSO): 1.89-1.91 (dd, $J_{ab}$: 15.62 Hz, $J_{ax}$: 3.17 Hz, 1H, Hs), 3.33-3.39 (dd, $J_{ab}$: 3.74 Hz, $J_{bx}$: 17.11 Hz, 1H, Hs), 3.65-3.80 (dd, $J_{ax}$: 3.54 Hz, $J_{bx}$: 16.91 Hz, 1H, Hs), 3.73-3.94 (m, 6H, methyl), 6.97-8.21 (m, 11H, Ar). $^{13}$C NMR (DMSO, ppm): 458 (M+, 50 %). Anal. Calcd. for C22H20ClN3O4S: C, 57.70; H, 4.40; N, 9.18. Found: C, 57.64; H, 4.45; N, 9.14.

2-[1-(4-Chloro-benzenesulfonyl)-5-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-pyrazol-3-yl]-pyridine (5q)

IR (cm$^{-1}$): 3321 (N-H stretch), 3084 (C-H Aromatic), 1624 (C=N stretch), 1466 (C-H deform), 1170, 1337 (sym., asym S(=O)$_2$ stretch). $^1$H NMR ($\delta$ ppm, DMSO): 1.91-1.94 (dd, $J_{ab}$: 17.36 Hz, $J_{ax}$: 3.21 Hz, 1H, Hs), 3.64-3.48 (dd, $J_{ab}$: 4.12 Hz, $J_{bx}$: 17.44 Hz, 1H, Hs), 3.69-3.85 (dd, $J_{ax}$: 3.28 Hz, $J_{bx}$: 16.55 Hz, 1H, Hs), 7.29-8.69 (m, 12H, Ar). $^{13}$C NMR (DMSO, ppm): 40.2 (CH$_2$ pyrazo-
line), 44.5 (CH pyrazoline), 124.6-149.2 (12CH Ar), 137.1-139.4 (2C benzene), 154.2 (C pyridine), 160.7 (C pyrazoline). MS (m/z): 432 (M⁺, 55%). Anal. Calcd. for C₂₀H₁₅Cl₂N₃O₂S: C, 55.56; H, 3.50; N, 9.72. Found: C, 55.60; H, 3.51; N, 9.68.

2-[1-(4-Chloro-benzenesulfonyl)-5-thiophen-2-yl-4,5-dihydro-1H-pyrazol-3-yl]-pyridine (5t)

IR (cm⁻¹): 3387 (N-H stretch), 3083 (C-H Aromatic), 1612 (C=N stretch), 1468 (C-H deform), 1167, 1389 (sym., asym S(=O)₂ stretch). ¹H NMR (δ ppm, DMSO): 1.90-1.93 (dd, J₀a: 17.23 Hz, J₀b: 3.32 Hz, 1H, Hₐ), 3.46-3.50 (dd, J₀a: 3.87 Hz, J₀b: 16.65 Hz, 1H, Hₐ), 3.82-3.89 (dd, J₂a: 3.14 Hz, J₂b: 16.91 Hz, 1H, H₁). ¹³C NMR (DMSO, ppm): 38.6 (CH₂ pyrazoline), 43.2 (C pyrazoline), 115.6-140.3 (12CH benzene), 144.9-157.1 (4C Ar), 161.3 (C pyrazoline). MS (m/z): 403 (M⁺, 25 %). Anal. Calcd. for C₇₈H₄₈Cl₆N₆O₇S₂: C, 53.53; H, 3.49; N, 10.40. Found: C, 53.49; H, 3.53; N, 10.37.

Biological evaluation

Study animals

The study protocols were authenticated by the Institutional Animal Ethics Committee (IAEC) with the protocol number BBDNIIT/IAEC/009/2014. Animal house, Faculty of Pharmacy, BBDNIIT, Lucknow, U.P., India provided animals (male albino mice) for the in-vivo study which were treated humanely and maintained under standard conditions of temperature (26 ± 2 °C), percent humidity (55 ± 5), light and dark cycles and free access to food and water.

Study design

The studies were performed as per reported procedures (Tripathi et al., 2016; Upadhyay et al., 2017). The detailed description of the groups and respective doses are given in Table 2.

Antidepressant activity

The antidepressant potential of the synthesized derivatives (5a-5t) was evaluated using behavioral in vivo tests in mice model, such as forced swim test (FST) and tail suspension test, (TST) as given by Porsolt (1981) and Willner and Mitchell (2002).

- Porsolt’s behavioral despair or FST

In FST, the state of despair can be minimized by different therapeutically effective antidepressants (Porsolt et al., 1977; Vogel, 2002). The duration of immobility in animals, produced by the test compounds, was measured by known procedures (Tripathi et al., 2016; Upadhyay et al., 2017).

- Tail suspension test (TST)

TST is another well known method (Steru et al., 1985; Vogel, 2002), employed to evaluate the antidepressant potential of the test compounds. In this test, the duration of immobility was measured by known procedures (Tripathi et al., 2016; Upadhyay et al., 2017).

Anti-anxiety activity

The maze model was used to evaluate anti-anxiety potential of the test compounds, which selectively identified the anxiolytic (open arm exploration time increased and time spent in closed arms decreased) and anxiogenic drugs (Vogel, 2002).

Elevated plus-maze test

The elevated plus-maze was used to determine anxiety-related behavior, measured by the extent to which the mouse avoids visiting the open arm of the maze (Lister, 1987; Pellow et al., 1985). After one hour of oral administration of the test compound, observations (i.e. time spent in closed arm and total number of the arm entries) were recorded during the 6 minute test duration by known procedures (Tripathi et al., 2016; Upadhyay et al., 2017).
Table 2: Data showing antidepressant, anti-anxiety and neurotoxicity studies of the synthesized 2-pyrazoline derivatives (5a-5t)

| Compounds | Group Number | Doses (mg/kg b.w.) | Duration of Immobility in FST (sec) (Mean±SD) | Duration of Immobility in TST (sec) (Mean±SD) | Number of Entries in Closed Arms (Mean±SD) | Time Spent in Closed Arms (sec) (Mean±SD) | Neurotoxicity Studies |
|-----------|--------------|--------------------|-----------------------------------------------|-----------------------------------------------|----------------------------------------------|------------------------------------------|----------------------|
|           |              |                    | Duration of Immobility in FST (sec) (Mean±SD) | Duration of Immobility in TST (sec) (Mean±SD) | Number of Entries in Closed Arms (Mean±SD) | Time Spent in Closed Arms (sec) (Mean±SD) | Rotarod Testc | Actophotometer Testd (Mean Counts) |
|           | Before Dose  | After Dose (After 1h) | Before Dose  | After Dose (After 1h) |
| 5a        | 1            | 50 125.17±8.93 177.83±17.27 10.83±3.66 162.00±21.54 0/6 0/6 291.83 298.00 |
|           | 2            | 100 89.50±11.11 174.00±19.97 14.00±2.53 126.33±11.50 1/6 0/6 277.33 284.50 |
| 5b        | 3            | 50 79.33±12.39 107.67±27.44 12.33±2.58 143.83±11.67 0/6 2/6 284.17 284.17 |
|           | 4            | 100 85.50±10.50 101.67±15.71 15.67±2.94 102.83±9.58 0/6 0/6 317.17 317.17 |
| 5c        | 5            | 50 82.67±6.41 136.50±18.29 6.83±1.47 194.33±13.59 0/6 0/6 440.17 430.67 |
|           | 6            | 100 68.50±15.73 122.83±10.03 7.67±2.94 188.33±15.68 0/6 0/6 275.50 277.67 |
| 5d        | 7            | 50 124.33±9.71 201.17±12.54 8.83±3.06 146.00±14.21 1/6 1/6 446.67 473.33 |
|           | 8            | 100 97.67±14.19 155.33±9.73 9.33±4.18 138.67±11.94 0/6 0/6 277.33 272.33 |
| 5f        | 9            | 50 105.17±13.85 97.50±30.25 5.17±2.32 196.33±13.43 0/6 0/6 470.33 461.17 |
|           | 10           | 100 87.83±18.79 76.50±20.69 6.50±1.87 211.83±15.25 0/6 1/6 286.17 283.50 |
| 5g        | 11           | 50 104.17±15.56 149.67±8.45 6.50±1.05 273.17±12.58 0/6 0/6 275.50 270.83 |
|           | 12           | 100 99.50±14.64 150.50±8.31 9.00±2.37 275.17±26.50 0/6 0/6 284.17 258.33 |
| 5h        | 13           | 50 155.00±11.64 93.00±11.17 3.67±1.63 198.50±19.38 0/6 0/6 477.83 517.50 |
|           | 14           | 100 101.67±12.26 149.17±42.10 5.17±2.32 255.67±28.39 0/6 0/6 286.17 301.00 |
| 5i        | 15           | 50 94.33±14.18 133.33±23.85 6.50±3.27 253.17±15.18 0/6 0/6 446.67 445.67 |
|           | 16           | 100 73.33±25.40 107.67±17.96 8.67±3.27 208.17±24.26 0/6 0/6 298.00 297.00 |
| 5j        | 17           | 50 112.50±19.15 129.50±37.25 8.00±2.28 222.17±16.80 0/6 0/6 486.67 488.67 |
|           | 18           | 100 84.67±13.34 132.17±11.32 9.50±1.87 193.67±20.22 0/6 0/6 286.17 281.83 |
| 5k        | 19           | 50 58.00±7.97 65.83±13.79 7.00±1.79 205.17±14.02 0/6 0/6 485.50 482.67 |
|           | 20           | 100 23.00±6.20 37.83±10.25 8.83±2.04 175.17±24.00 0/6 0/6 286.17 282.83 |
| Compounds | Group Number | Doses (mg/kg b.w.) | Antidepressant Activity\textsuperscript{a} | Anti-anxiety Activity\textsuperscript{b} | Neurotoxicity Studies |
|-----------|--------------|-------------------|--------------------------------|--------------------------------|------------------|
|           |              |                   | Duration of Immobility in FST (sec) (Mean±SD) | Duration of Immobility in TST (sec) (Mean±SD) | Number of Entries in Closed Arms (Mean±SD) | Time Spent in Closed Arms (sec) (Mean±SD) | Before Dose | After Dose (After 1h) |
|           |              |                   | Duration of Immobility in FST (sec) (Mean±SD) | Duration of Immobility in TST (sec) (Mean±SD) | Number of Entries in Closed Arms (Mean±SD) | Time Spent in Closed Arms (sec) (Mean±SD) | Before Dose | After Dose (After 1h) |
| 5l        | 21           | 50                | 59.67±9.93 | 129.17±19.33 | 7.67±3.20 | 164.83±14.74 | 1/6 | 1/6 | 275.50 | 269.33 |
|           | 22           | 100               | 43.50±8.04 | 54.83±15.88 | 9.17±2.32 | 137.83±10.46 | 0/6 | 0/6 | 284.17 | 282.50 |
| 5q        | 23           | 50                | 73.00±17.13 | 107.50±17.90 | 8.83±2.32 | 214.17±15.22 | 0/6 | 0/6 | 286.17 | 288.33 |
|           | 24           | 100               | 70.50±16.96 | 76.67±6.59 | 12.50±2.07 | 170.33±18.00 | 0/6 | 1/6 | 275.50 | 274.67 |
| 5r        | 25           | 50                | 158.33±9.07 | 114.50±13.13 | 2.50±2.43 | 225.17±22.44 | 0/6 | 0/6 | 284.17 | 279.17 |
|           | 26           | 100               | 103.83±10.11 | 100.83±11.75 | 4.00±3.03 | 233.33±22.65 | 0/6 | 0/6 | 279.17 | 276.00 |
| 5t        | 27           | 50                | 107.50±8.87 | 101.17±14.97 | 7.33±2.25 | 274.17±19.03 | 0/6 | 0/6 | 281.67 | 272.83 |
|           | 28           | 100               | 79.67±11.48 | 76.67±6.59 | 8.50±2.81 | 257.67±34.37 | 0/6 | 0/6 | 277.33 | 287.00 |
| Control (CMC) | 29           | 0.5%              | 179.67±18.67 | 219.00±17.56 | 0.83±0.75 | 281.67±41.09 | 0/6 | 0/6 | 410.33 | 394.17 |
| Standard drug (Imipramine) | 30           | 10                | 29.33±8.43 | 60.33±9.33 | --- | --- | 0/6 | 1/6 | 399.50 | 404.83 |
| Standard drug (Diazepam) | 31           | 2                 | --- | --- | 9.33±3.08 | 177.33±45.18 | 0/6 | 0/6 | 228.00 | 239.67 |

Bold data represents the most active compounds in the series.

\( n = 6 \) (Number of animals tested at each dose level); \( p < 0.05 \).

**Control:** Carboxy methyl cellulose (CMC, 0.5 % suspension).

**Standard:** Imipramine (10 mg/kg, b.w.) for antidepressant activity and Diazepam (2 mg/kg, b.w.) for anti-anxiety activity.

\textsuperscript{a} The reduction in time of immobility in FST and TST are an established way to evaluate effectiveness of antidepressants.

\textsuperscript{b} The number of entries is increased in anxiolytic agents and decrease in anxiogenic agents and the amount of time spent in closed arms is decreased in anxiolytic agents and increase in anxiogenic agents.

\textsuperscript{c} Neurotoxicity was evaluated in Rotarod test before dosing and after 1 hour of dosing (number of animals exhibiting toxicity/number of animals tested).

\textsuperscript{d} Neurotoxicity recorded in actophotometer test (Counts recorded in 10 minutes duration).
Neurotoxicity study
This study was used to evaluate the effect of the compounds on the CNS, employing various behavioral tests, such as rotarod, open-field/actophotometer, turning on flat surface and inclined plane tests in mice model (Vogel, 2002; Parasuraman, 2011).

Neuromuscular coordination study
The effect of the compounds on motor coordination, where relaxation of skeletal muscle is produced, was examined, as per method given by Dunham and Miya in 1957, with slight modification (Vogel et al., 2002).

Locomotor activity (actophotometer test)
Locomotor activities of the animals were used as an index of their mental alertness, which is affected (increased or decreased) by majority of the CNS acting drugs (Dhingra and Goyal, 2008; Tripathi et al., 2016; Upadhyay et al., 2017).

Acute toxicity study
The consequences (changes in skin and fur, behavior patterns, convulsions, tremors and death) of a single dose on a particular animal species was determined by acute toxicity testing. In this study, acute oral toxicity (LD50) of two most active final derivatives (5b and 5k) was performed as per guidelines laid by Organization for Economic Co-operation and Development (OECD) guideline No 423 “Acute Oral Toxicity - Acute Toxic Class Method” using known procedures (OECD, 2001).

Computational studies
Molecular docking simulations were used to predict binding affinity and binding orientations of the synthesized compounds to the MAO-A protein (PDB ID: 2Z5X), with the help of GLIDE program (Schroedinger, LLC, 2014), using known procedures (Tripathi et al., 2016; Upadhyay et al., 2017). QikProp module of Schroedinger software program was successfully employed for in silico prediction of ADME properties of the synthesized derivatives. Furthermore, for in silico toxicity prediction of the synthesized compounds, two freely accessible computer programs (LAZAR and OSIRIS Property explorer) were employed. Among them, LAZAR provided a generic tool for predicting complex toxicological end points (like long-term toxicity, reproductive toxicity and carcinogenicity). OSIRIS program calculated various drug-related properties of chemical structures and risks of untoward effects, which are considered as an indication of drug-conform behavior (Klebe, 2000).

RESULTS AND DISCUSSION

A total of fourteen 1,3,5-trisubstituted 2-pyrazoline derivatives (5a-5t) were prepared through Claisen-Schmidt condensation, followed by heterocyclization and substitution with 4-chlorobenzenesulfonyl chloride using both, conventional and MAOS methods. The microwave assisted procedures were developed for the first time to synthesize the final 1,3,5-trisubstituted-2-pyrazoline derivatives. The research outcomes suggested that almost all the derivatives synthesized by this technique were obtained at a faster rate and in a better synthetic yield in comparison to conventional procedures. The prepared derivatives were analyzed by various physicochemical (Table 1) and spectral techniques and results comply with the proposal. The IR spectra reflect some characteristic absorption bands in the corresponding regions to C=N str (1509-1612 cm⁻¹), N-H str (3449-3107 cm⁻¹) and C-H deform (1431-1354 cm⁻¹). In the third step derivatives, a characteristic peak of sulfonyl group was also observed in the IR spectra. ¹H-NMR spectra showed that two dissimilar methylene protons (Hₐ/Hₖ) were visible at δ 2.92–3.38 ppm, 3.70–3.93 which coupled themselves and with the me-
thine proton (H₆) at δ 6.67–7.03 in vicinity. The other values were in congruence with the corresponding aliphatic and aromatic protons.

The pharmacological results (Table 2 and Figure 2) demonstrated that number of entries in closed and open arms, in the elevated plus maze test, increased significantly with a lesser closed arm exploration time (Figure 2a and 2b) for Compound 5b and Compound 5k showed the best antidepressant action (Figure 2c and 2d) in FST and TST models at the evaluated doses. The pharmacological actions of the prepared analogs were observed in a dose dependent manner, as the magnitude of the effects increased at higher tested doses (100 mg/kg b.w.). The structure activity relationship studies established that C-3 naphthalen-1-yl substitution and C-5 furan-2-yl substitution at 2-pyrazoline nucleus were crucial for the antidepressant activity (5k). However, a polar substitution of 4-hydroxyphenyl group at 3rd position (5b) was essential in eliciting anxiolytic activity.

![Image](image_url)

**Figure 2:** (a) Anti-anxiety activity (Number of entries in closed arms in Elevated Plus Maze Test); (b) Anti-anxiety activity (Time spent in closed arms in Elevated Plus Maze Test).
MAOs are considered as an important biological target to develop drugs against certain mental disorders, such as depression and anxiety. It has been also established that the 2-pyrazoline derivatives possess excellent affinity towards MAO isoforms, as reported in previous literatures. Docking studies allowed to gain some structural inputs towards binding characteristics of the prepared derivatives with the MAO-A target protein. The most stable conformation of ligand-protein complex and the interaction studies of the most active compounds, 5b and 5k at the MAO-A protein binding pocket have been depicted in Figure 3 and 4. Docking studies inferred that Ala 68, Tyr69 and Phe352 are some important residues interacting at the MAO-A binding pocket. It was evident that at 2-pyrazoline nucleus, N1 p-chlorobenzenesulfonyl substitution proved to
be very useful and all the compounds having this substitution showed better activity than the N1 unsubstituted pyrazolines (Tripathi et al., 2016). The presence of sulfonyl group at N1 position of 2-pyrazoline nucleus evidenced H-bonding interaction between sulfonyl oxygen and Ala68 and Tyr69 residues at the MAO-A binding pocket. It was demonstrated in previous works that ligands having such type of hydrogen bond interactions are well placed in the aromatic cage of the MAO protein possessing C5 furyl/ substituted phenyl ring and N1-benzenesulfonyl ring of 2-pyrazoline nucleus. The naphthyl/4-chlorophenyl rings showed, imperative pi-pi stacking interactions with Phe352 backbone residue. It was also evident that most of the interactions of PDB co-crystal ligand 2Z5X were conserved in compounds 5b and 5k. Furthermore, the predicted binding affinity (Glide gscores) of the prepared analogs complemented well with the in vivo anti-anxiety and antidepressant activities data.

The synthesized compounds were also tested for their probable neurotoxicological effects, such as motor coordination (rotarod test) and locomotor activity (actophotometer test). The obtained results suggested that these derivatives were completely free from severe neurotoxicity (motor co-ordinations and locomotor disturbances) threats at the evaluated doses (Table 2). In Rotarod test, the mean fall-off time of most of the mice was greater than 180 seconds, and hence these compounds may not affect the motor coordination of the animals. Also, the mean counts in actophotometer test in pre-dose studies, and after 1 hour of dosing, were not significantly different and therefore, any probability of CNS stimulating or depressing effects of the tested compounds was ruled out. Additionally, most potent derivatives were evaluated for their acute toxicity at the corresponding doses. None of them showed any changes in behavioral pattern, convulsions, tremors, skin changes and death throughout the 14 days acute toxicity studies. Also, encouraging in silico pharmacokinetic properties (Table 3) were observed. Moreover, the screened compounds were not liable to cause carcinogenicity, mutagenicity, reproductive toxicity, acute toxicity and irritancy. Therefore, they were regarded to be safe as was corroborated by the computational programs such as LAZAR and OSIRIS (Table 4).

**CONCLUSION**

This study concludes that the synthesized 2-pyrazoline analogs possess excellent to good antidepressant and anti-anxiety potential, as evaluated using various in vivo methods. The presence of C-3 naphthalen-1-yl substitution and C-5 furan-2-yl substitution at 2-pyrazoline nucleus was decisive for the antidepressant activity (5k). However, a polar substitution of 4-hydroxyphenyl group at 3rd position (5b) was essential in eliciting anxiolytic activity. Nearly all the compounds were completely free from any neurotoxic indications, with a complementary pharmacokinetic behavior as predicted by in silico methods. Molecular docking experiments ascertained some imperative interactions of these compounds with the target protein, playing a pivotal role in neuropharmacology. Thus, in a nutshell, the synthesized 2-pyrazoline derivatives may prove their worth in the treatment and management of certain mental disorders, possibly through MAO-A inhibition.
Figure 3: Ligand receptor interaction diagram of compound 5b at the binding site of MAO-A protein (PDB ID: 2Z5X) showing best anti-anxiety activity. (a) 2D Ligand receptor interaction diagram. (b) 3D Ligand receptor interaction diagram.
Figure 4: Ligand receptor interaction diagram of compound 5k at the binding site of MAO-A protein (PDB ID: 2Z5X) showing best antidepressant activity. (a) 2D Ligand receptor interaction diagram. (b) 3D Ligand receptor interaction diagram.
Table 3: *In silico* prediction of binding affinity (Glide gscore) and ADME parameters of the synthesized 1,3,5-trisubstituted-2-pyrazoline derivatives (5a-5t)

| Compounds | Glide gscore | #Stars | MW     | Volume   | PSA   | SASA   | Donar-HB | AcceptorHB | CNS   | QPlogBB | QlogP o/w | QPlogKhsa | QPPCaco | Site of metab | % Human Oral absorption | Violations of Rule of Five |
|-----------|--------------|--------|--------|----------|-------|--------|----------|------------|-------|---------|----------|-----------|---------|---------------|--------------------------|--------------------------|
| 5a        | -7.36        | 0      | 472.94 | 1272.98  | 86.63 | 666.85 | 1        | 7.75  | -1      | -0.80   | 3.70      | 0.35    | 582.26 | 5             | 100                      | 0                         |
| 5b        | -8.91        | 0      | 447.34 | 1184.44  | 73.71 | 639.41 | 1        | 6.25   | 0       | -0.53   | 4.08      | 0.50    | 557.41 | 3             | 100                      | 0                         |
| 5c        | -8.75        | 0      | 402.85 | 1094.53  | 82.24 | 602.32 | 1        | 6.75   | 0       | -0.68   | 3.09      | 0.16    | 520.10 | 4             | 93.64                    | 0                         |
| 5d        | -8.10        | 0      | 418.91 | 1130.25  | 74.61 | 622.66 | 1        | 6.25   | 0       | -0.60   | 3.65      | 0.35    | 538.82 | 4             | 100                      | 0                         |
| 5f        | -7.73        | 1      | 465.78 | 1205.86  | 51.17 | 651.08 | 0        | 5.50   | 1       | 0.20    | 5.09      | 0.56    | 1836.33 | 2             | 100                      | 1                         |
| 5g        | -8.82        | 0      | 421.30 | 1115.91  | 59.71 | 613.96 | 0        | 6.00   | 1       | 0.05    | 4.04      | 0.17    | 1713.80 | 3             | 100                      | 0                         |
| 5h        | -7.80        | 1      | 437.36 | 1151.77  | 52.08 | 634.43 | 0        | 5.50   | 1       | 0.14    | 4.66      | 0.41    | 1775.53 | 3             | 100                      | 0                         |
| 5i        | -8.78        | 0      | 507.00 | 1389.36  | 64.30 | 720.45 | 0        | 7.00   | 0       | -0.21   | 5.16      | 0.61    | 2166.91 | 4             | 90.92                    | 2                         |
| 5j        | -9.06        | 1      | 481.40 | 1294.00  | 51.34 | 690.76 | 0        | 5.50   | 1       | 0.078   | 5.579     | 0.82    | 2146.71 | 2             | 100                      | 1                         |
| 5k        | -9.24        | 1      | 436.91 | 1204.01  | 59.87 | 652.93 | 0        | 6.00   | 0       | -0.09   | 4.52      | 0.42    | 1972.42 | 3             | 100                      | 0                         |
| 5l        | -8.36        | 0      | 452.97 | 1240.41  | 52.23 | 673.58 | 0        | 5.50   | 1       | 0.01    | 5.14      | 0.66    | 2055.46 | 3             | 100                      | 1                         |
| 5q        | -7.20        | 0      | 457.93 | 1240.78  | 76.47 | 652.37 | 0        | 8.00   | -1      | -0.36   | 3.46      | -0.09   | 1384.40 | 5             | 100                      | 0                         |
| 5r        | -8.59        | 0      | 432.32 | 1152.67  | 63.55 | 624.66 | 0        | 6.50   | 0       | -0.10   | 3.92      | 0.14    | 1315.15 | 3             | 100                      | 0                         |
| 5t        | -8.12        | 0      | 403.90 | 1099.01  | 64.46 | 608.64 | 0        | 6.50   | 0       | -0.17   | 3.48      | -0.02   | 1263.71 | 4             | 100                      | 0                         |
| 2Z5X      | -6.89        | 0      | 212.25 | 733.39   | 33.50 | 381.35 | 1        | 1.75   | 0       | 0.18    | 3.11      | 0.222   | 840.62  | 3             | 100                      | 0                         |

#stars: Number of property or descriptor values that fall outside the 95 % range of similar values for known drugs; Volume: Total solvent accessible volume in cubic angstrom using a probe with 1.4 Å radius; PSA: Van der Waals polar surface area of nitrogen and oxygen atoms; SASA: Total solvent accessible surface area in square angstrom using a probe with 1.4 Å radius; donarHB: Hydrogen bond donor; acceptorHB: Hydrogen bond acceptor; CNS: Predicted central nervous system activity at -2 (inactive) to +2 (active) scale; QPlogBB: Predicted brain/blood partition coefficient; QlogPo/w: Predicted octanol-water partition coefficient. QPlogKhsa: Prediction of binding to human serum albumin; QPPCaco: Predicted apparent Caco-2 cell permeability in nm/sec; metab: Number of likely metabolic reactions; Number of violations of Lipinski’s rule of five.
Table 4: *In silico* toxicity prediction data of the synthesized 1,3,5-trisubstituted -2-pyrazoline derivatives (5a-5t)

| Compounds | Toxicity prediction |  |
|-----------|---------------------|---|
|           | OSIRIS PROPERTY EXPLORER | LAZAR |
|           | Mutagenic | Tumorigenic | Irritant | Reproductive effect | Maximum recommended daily dose (mmol) | Mutagenicity | Acute toxicity LC50 (mmol) | Carcinogenic potency |
| 5a        | -         | -          | -        | -                  | 4.23e+00                           | -           | 5.51e+00                     | -                      |
| 5b        | -         | -          | -        | -                  | 4.62e+00                           | -           | 1.38e+01                     | -                      |
| 5c        | -         | -          | -        | -                  | 1.44e+01                           | -           | 2.31e+01                     | -                      |
| 5d        | -         | -          | -        | -                  | 1.50e+01                           | -           | 2.61e+01                     | -                      |
| 5f        | -         | -          | -        | -                  | 6.86e+00                           | -           | 8.78e+00                     | -                      |
| 5g        | -         | -          | -        | -                  | 1.25e+01                           | -           | 1.01e+01                     | -                      |
| 5h        | -         | -          | -        | -                  | 1.30e+01                           | -           | 9.11e+00                     | -                      |
| 5i        | +         | -          | -        | -                  | 4.52e+00                           | -           | 4.10e+00                     | +                      |
| 5j        | +         | -          | -        | -                  | 8.67e+00                           | -           | 7.05e+00                     | -                      |
| 5k        | +         | -          | -        | -                  | 1.47e+01                           | -           | 8.28e+00                     | -                      |
| 5l        | +         | -          | -        | -                  | 1.37e+01                           | -           | 1.03e+01                     | +                      |
| 5q        | -         | -          | -        | -                  | 1.02e+01                           | -           | 3.03e+00                     | -                      |
| 5r        | -         | -          | -        | -                  | 4.24e+01                           | -           | 5.34e+00                     | -                      |
| 5t        | -         | -          | -        | -                  | 2.16e+02                           | -           | 7.31e+00                     | +                      |

No risk: (-); Medium risk: (+); High risk: (++)
Acknowledgements

The authors would like to thank Central Drugs Research Institute (CDRI), Lucknow, India and Department of Chemistry, Banasthali Vidyapith University, Banasthali, Rajasthan, India for providing the library and sophisticated analytical instrument facilities. We would extend our sincere gratitude to the All India Council for Technical Education (AICTE), New Delhi, India, for providing grant under the Research Promotion Scheme (Grant No.: 8023/RID/RPS/30 (Pvt.) 2011-12), through which the computational software facility has been made available at the host institute and the technical support team/application scientists of Schrödinger Inc. for their help during implementation of the project.

Conflict of interest

No conflict of interest is reported by the authors.

REFERENCES

Agrawal M, Sonar PK, Saraf SK. Synthesis of 1,3,5-trisubstituted pyrazoline nucleus containing compounds and screening for antimicrobial activity. Med Chem Res. 2012;21:3376-81.

Amrein R, Martin JR, Cameron AM. Moclobemide in patients with dementia and depression. Adv Neurol. 1999;80:509-19.

Bhandari S, Tripathi AC, Saraf SK. Synthesis and anticonvulsant activity of some 2-pyrazoline derivatives Med Chem Res. 2013;22:5290-6.

Brown CS, Kent TA, Bryant SG, Gevedon RM, Campbell JL, Felthous AR, et al. Blood platelet uptake of serotonin in episodic aggression. Psychiatry Res. 1989;27:5-12.

Cesura AM, Pletscher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res. 1992;38:171-297.

Chimenti F, Bolasco A, Manna F, Secchi D, Chimenti P, Befani O, et al. Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase. J Med Chem. 2004;47:2071-4.

Chimenti F, Carradori S, Secchi D, Bolasco A, Bizzarri B, Chimenti P, et al. Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-(di(hetero)aryl)-4,5-dihydro-(1H)-pyrazole derivatives. Eur J Med Chem. 2010;45:800-4.

Dhingra D, Goyal PK. The CNS depressant drugs such as barbiturates and alcohol reduce the motor activity while the stimulants such as caffeine and amphetamines increase the activity. Indian J Exp Biol. 2008;46:212-8.

Dunham NW, Miya TS. A note on a simple apparatus for detecting neurological deficit in rats and mice. J Am Pharm Assoc Am Pharm Assoc. 1957;46:208-9.

Foley P, Gerlach M, Youdim MB, Riederer P. MAO-B inhibitors: multiple roles in the therapy of neurodegenerative disorders? Parkinsonism Relat Disord. 2000;6:25-47.

Gareri P, Falconi U, De Fazio P, De Sarro, G. Conventional and new antidepressant drugs in the elderly. Prog Neurobiol. 2000;61:353-96.

Gautam, V, Chawla V, Sonar PK, Saraf SK. Syntheses, characterization and antimicrobial evaluation of Some 1, 3, 5-trisubstituted pyrazole derivatives. E-Journal of Chemistry. 2010;7:1190-5.

Gokhan N, Yesilada A, Ucar G, Erol K, Bilgin AA. 1-N-substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines: synthesis and evaluation as MAO inhibitors. Arch Pharm (Weinheim). 2003;336:362-71.

Gokhan-Kelekci N, Koyunoglu S, Yabanoglu S, Yelekci K, Ozgen O, Ucar G, et al. New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity. Bioorg Med Chem. 2009;7:675-89.

Jagrat M, Behera J, Yabanoglu S, Ercan A, Ucar G, Sinha BN, et al. Pyrazoline-based MAO-B inhibitors: synthesis, biological evaluation and structural determinants of MAO-A and MAO-B selectivity. Bioorg Med Chem Lett. 2011;21:4296-300.

Jayaprakash V, Sinha BN, Ucar G, Ercan A. Pyrazoline-based mycobactin analogues as MAO-inhibitors. Bioorg Med Chem Lett. 2008;18:6362-8.

Kaplancikli ZA, Ozdemir A, Turan-Zitouni G, Altintop MD, Can OD. New pyrazoline derivatives and their antidepressant activity. Eur J Med Chem. 2010;45:4383-7.

Karuppasamy M, Mahapatra M, Yabanoglu S, Ucar G, Sinha BN, Basu A, et al. Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorg Med Chem. 2010;18:1875-81.
Klebe G. Recent developments in structure-based drug design. J Mol Med. 2000;78:269–81.

Lidstrom P, Tierney J, Wathey B, Westman J. Microwave assisted organic synthesis- a review. Tetrahedron. 2001;57:9225-83.

Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl). 1987;92:180-5.

Maccioni E, Alcaro S, Orallo F, Cardia C, Distinto S, Costa G, et al. Synthesis of new 3-aryl-4,5-dihydro-pyrazole-1-carbothioamide derivatives. An investigation on their ability to inhibit monoamine oxidase. Eur J Med Chem. 2010;45:4490-8.

Manna F, Chimenti F, Bolasco A, Secci D, Bizzarri B, Befani O, et al. Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorg Med Chem Lett. 2002;12:3629-33.

Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63:1209-16.

Mishra N, Sasmal D. Development of selective and reversible pyrazolyl based MAO-B inhibitors: virtual screening, synthesis and biological evaluation. Bioorg Med Chem Lett. 2011;21:1969-73.

Mitoma J, Ito A. Mitochondrial targeting signal of rat liver monoamine oxidase B is located at its carboxy terminus. J Biochem. 1992;111:20-4.

OECD Guidelines for Testing of Chemicals 423: Acute Oral Toxicity - Acute Toxic Class Method. Paris: Organization for Economic Corporation and Development, 2001.

Ozdemir Z, Kandilci HB, Gumusel B, Calis U, Bilgin AA. Synthesis and studies on antidepressant and anti-convulsant activities of some 3-(2-thienyl)pyrazoline derivatives. Arch Pharm (Weinheim). 2008;341:701-7.

Palaska E, Aytemir M, Uzbay IT, Erol D. Synthesis and antidepressant activities of some 3,5-diphenyl-2-pyrazolines. Eur J Med Chem. 2001;36:539-43.

Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods. 1985;14:149-67.

Pletscher A. The discovery of antidepressants: a winding path. Experientia. 1991;47:4-8.

Porsolt RD. Antidepressants. New York: Raven Press, 1981.

Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther. 1977;229:327-36.

Rajendra Prasad Y, Lakshmana Rao A, Prasoona L, Murali K, Ravi Kumar P. Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2''-hydroxy naphthalen-1''-yl)-1,5-diphenyl-2-pyrazolines. Bioorg Med Chem Lett. 2005;5:5030-4.

Ruhoglu O, Ozdemir Z, Calis U, Gunusel B, Bilgin AA. Synthesis of and pharmacological studies on the antidepressant and anticonvulsant activities of some 1,3,5-trisubstituted pyrazolines. Arzneimittelforschung. 2005;55:431-6.

Sahoo A, Yabanoglu S, Sinha BN, Ucar G, Basu A, Jayaprakash V. Towards development of selective and reversible pyrazoline based MAO-inhibitors: Synthesis, biological evaluation and docking studies. Bioorg Med Chem Lett. 2010;20:132-6.

Steru L, Chermat R, Thierry B, Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985;85:367-70.

Thase ME. The role of monoamine oxidase inhibitors in depression treatment guidelines. J Clin Psychiatry. 2012;73(Suppl 1):10-6.

Tripathi AC, Upadhyay S, Paliwal S, Saraf SK. An expeditious one-pot microwave facilitated versus conventional syntheses: In vivo biological screening and molecular docking studies of some 3,5-disubstituted-4,5-dihydro-(1H)-pyrazole derivatives. Med Chem Res. 2016;25:390-406.

Upadhyay S, Tripathi AC, Paliwal S, Saraf SK. 2-Pyrazoline derivatives in neuropharmacology: synthesis, ADME prediction, molecular docking and in-vivo biological evaluation. EXCLI J. 2017;16:628-49.

Vogel HG. Drug discovery and evaluation: pharmacological assays. 2nd ed. Berlin: Springer-Verlag, 2002.

Volz HP, Gleiter CH. Monoamine oxidase inhibitors. A perspective on their use in the elderly. Drugs Aging. 1998;13:341-55.

Willner P, Mitchell PJ. The validity of animal models of predisposition to depression. Behav Pharmacol. 2002;13:169-88.
Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat Rev Neurosci. 2006;7:295-309.

Zeller EA, Barsky J. In vivo inhibition of liver and brain monoamine oxidase by l-Isonicotinyl-2-isopropyl hydrazine. Proc Soc Exp Biol Med. 1952;81:459-61.